No abstract available
Keywords:
Fabry disease; Fabry’s disease; adult; agalsidase α; agalsidase β; alphagalactosidase; angiokeratoma; cardiac myocytes; cardiovascular disease; cause of death; enzyme replacement therapy; female; follow-up studies; genetic renal disease; humans; kidney biopsy; kidney transplantation; longevity; male; podocyte; progression of renal failure; renal dialysis; renal function decline; vascular disease; vascular endothelium.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Early Diagnosis
-
Enzyme Replacement Therapy
-
Fabry Disease* / diagnosis
-
Fabry Disease* / epidemiology
-
Fabry Disease* / genetics
-
Fabry Disease* / therapy
-
Genetic Predisposition to Disease
-
Humans
-
Isoenzymes / therapeutic use
-
Kidney Diseases* / diagnosis
-
Kidney Diseases* / epidemiology
-
Kidney Diseases* / genetics
-
Kidney Diseases* / therapy
-
Mutation
-
Phenotype
-
Predictive Value of Tests
-
Prognosis
-
Recombinant Proteins / therapeutic use
-
Risk Assessment
-
Risk Factors
-
alpha-Galactosidase / genetics
-
alpha-Galactosidase / therapeutic use
Substances
-
Isoenzymes
-
Recombinant Proteins
-
agalsidase alfa
-
GLA protein, human
-
alpha-Galactosidase
-
agalsidase beta